36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
Pauligk, C, Tannapfel, A, Meiler, J, Luley, K.B, Kopp, H.G, Homann, N, Hofheinz, R.D, Schmalenberg, H, Probst, S, Haag, G.M, Egger, M, Behringer, D.M, Stoehlmacher, J, Prasnikar, N, Block, A, Trojan, J, Folprecht, G, Pohl, M, Schirmacher, P, Al-Batran, S.E
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO
Lorenzen, S., Thuss-Patience, P.C., Folprecht, G., Riera Knorrenschild, J., Heinemann, V., Goekkurt, E., Dechow, T.N., Ettrich, T.J., Luley, K.B., Moulin, J-C., Lindig, U., Angermeier, S., Waidmann, O., Pink, D., Bolling, C., Junge, S., Pauligk, C., Gaiser, T., Götze, T.O., Al-Batran, S-E.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
Pauligk, C., Götze, T.O., Thuss-Patience, P.C., Riera-Knorrenschild, J., Goekkurt, E., Ettrich, T.J., Pink, D., Lindig, U., Luley, K.B., Dechow, T., Bitzer, M., Angermeier, S., Homann, N., Kullmann, F., Schuch, G., Bolling, C., Junge, S., Hofheinz, R.D., Lorenzen, S., Al-Batran, S-E.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Home parenteral nutrition (HPN) using individually compounded PN via A 7/8/9-Multi-chamber system versus PN via 2/3-chamber bags in subjects with metastatic or localized solid tumors requiring HPN - The IKF-010 Pekannuss trial
Al-Batran, S.-E., Roetzer, I., Wohn, L., Blau, W., Zander, T., Luley, K.B., Ivanyi, P., Hofheinz, R.-D., Groschek, M., Kreiss-Sender, J., Baur, C., Wolff, T., Wenning, B., Decker-Baumann, C., Bouymayan, S., Sookthai, D., Schaaf, M., Riedel, J., Goetze, T.O., Haag, G.M.
Published in Clinical nutrition ESPEN (01.12.2023)
Published in Clinical nutrition ESPEN (01.12.2023)
Get full text
Journal Article